Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
96 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07761351 | A Randomized Controlled Trial Comparing Percutaneous CT-Guided Biopsy and Shape-Sensing Robotic-Assisted Bronchoscopy(ENCOMPASS) | recruiting | Phase 4 | 550 | Intuitive SurgicalINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT06651970 | Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure | recruiting | Phase 4 | 60 | AstraZenecaINDUSTRY | 6 | Sep 24, 2026 | clinicaltrials |
| NCT07218341 | A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 4 | 150 | Eli Lilly and CompanyINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| NCT07176689 | Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) | recruiting | Phase 4 | 50 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 6 | Sep 14, 2026 | clinicaltrials |
| NCT06274515 | A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies(REMERGE) | recruiting | Phase 4 | 320 | Hoffmann-La RocheINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT03975829 | Pediatric Long-Term Follow-up and Rollover Study | active not recruiting | Phase 4 | 163 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 27, 2026 | clinicaltrials |
| NCT01742299 | Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator | completed | Phase 4 | 155 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 18, 2026 | clinicaltrials |
| NCT06183437 | The STOP-MED CTRCD Trial(STOP-MED CTRCD) | recruiting | Phase 4 | 335 | Dinesh ThavendiranathanOTHER | 6 | Jul 7, 2026 | clinicaltrials |
| NCT04877522 | Asciminib Roll-over Study | recruiting | Phase 4 | 347 | Novartis PharmaceuticalsINDUSTRY | 29 | Jul 6, 2026 | clinicaltrials |
| NCT06440629 | Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)(RA-DRUM) | active not recruiting | Phase 4 | 387 | Diakonhjemmet HospitalOTHER | 6 | Jul 1, 2026 | clinicaltrials |
| NCT00771199 | An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain | completed | Phase 4 | 14 | Janssen-Cilag Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05803941 | Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | recruiting | Phase 4 | 700 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 4, 2026 | clinicaltrials |
| NCT05864846 | A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex(EpiCom) | completed | Phase 4 | 79 | Jazz PharmaceuticalsINDUSTRY | 4 | Apr 27, 2026 | clinicaltrials |
| NCT05203172 | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | recruiting | Phase 4 | 46 | PfizerINDUSTRY | 17 | Apr 7, 2026 | clinicaltrials |
| NCT06876649 | A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib | recruiting | Phase 4 | 787 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT06876662 | A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma | recruiting | Phase 4 | 279 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT06748001 | Avapritinib Rollover Study | recruiting | Phase 4 | 60 | Blueprint Medicines CorporationINDUSTRY | 6 | Feb 9, 2026 | clinicaltrials |
| NCT06717919 | HOPE Against Cancer Recurrence in HCC(HOPE4Cancer) | recruiting | Phase 4 | 220 | Philipp DutkowskiOTHER | 17 | Dec 16, 2025 | clinicaltrials |
| NCT03229200 | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | active not recruiting | Phase 4 | 297 | Pharmacyclics Switzerland GmbHINDUSTRY | 17 | Oct 30, 2025 | clinicaltrials |
| NCT01496313 | To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer | completed | Phase 4 | 81 | SanofiINDUSTRY | 9 | Oct 3, 2025 | clinicaltrials |
| NCT01909934 | Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma | completed | Phase 4 | 50 | TakedaINDUSTRY | 10 | Sep 19, 2025 | clinicaltrials |
| NCT04362072 | Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer | completed | Phase 4 | 71 | PfizerINDUSTRY | 7 | Jun 11, 2025 | clinicaltrials |
| NCT00212433 | Optimisation and Performance of Reduced Preparation CT Colography | completed | Phase 4 | 120 | London North West Healthcare NHS TrustOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT01673984 | GP Extended Action Triptorelin(GREAT) | terminated | Phase 4 | 27 | IpsenINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT02312960 | Radium-223 Dichloride Long-term Follow-up Program | completed | Phase 4 | 255 | BayerINDUSTRY | 22 | Mar 25, 2025 | clinicaltrials |
| NCT01926496 | Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% | completed | Phase 4 | 485 | LEO PharmaINDUSTRY | 3 | Mar 7, 2025 | clinicaltrials |
| NCT05387525 | A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp(AKtive) | active not recruiting | Phase 4 | 447 | Almirall, S.A.INDUSTRY | 6 | Feb 11, 2025 | clinicaltrials |
| NCT04524442 | Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients | completed | Phase 4 | 42 | Advanced Accelerator ApplicationsINDUSTRY | 4 | Jan 24, 2025 | clinicaltrials |
| NCT06627036 | Dermoscopy vs Standard Marking for the Completeness of Excision of Keratinocyte Skin Cancers: The ClearMark Trial(ClearMark) | recruiting | Phase 4 | 1,376 | Hull University Teaching Hospitals NHS TrustOTHER_GOV | 1 | Jan 24, 2025 | clinicaltrials |
| NCT03285763 | A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)(TAIL) | completed | Phase 4 | 619 | Hoffmann-La RocheINDUSTRY | 24 | Jan 23, 2025 | clinicaltrials |
| NCT04078152 | Durvalumab Long-Term Safety and Efficacy Study(WAVE) | completed | Phase 4 | 163 | AstraZenecaINDUSTRY | 31 | Dec 20, 2024 | clinicaltrials |
| NCT01977651 | A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide(UPWARD) | completed | Phase 4 | 424 | Astellas Pharma Global Development, Inc.INDUSTRY | 20 | Dec 6, 2024 | clinicaltrials |
| NCT02116582 | A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer | completed | Phase 4 | 215 | Astellas Pharma Europe B.V.INDUSTRY | 5 | Dec 6, 2024 | clinicaltrials |
| NCT03963102 | Duration of Ameluz Application in Acral Actinic Keratoses Response | terminated | Phase 4 | 28 | Royal Cornwall Hospitals TrustOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT02154789 | An Assessment of Intra-lesional 3% Polidocanol Solution in the Treatment of Digital Myxoid Cyst | terminated | Phase 4 | 10 | University of EdinburghOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT03301857 | Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 | completed | Phase 4 | 85 | AmgenINDUSTRY | 8 | May 20, 2024 | clinicaltrials |
| NCT03817853 | An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma | completed | Phase 4 | 114 | Hoffmann-La RocheINDUSTRY | 7 | Apr 4, 2024 | clinicaltrials |
| NCT04931615 | ARTISS a Single-centre Randomised Control Study(ARTISS) | completed | Phase 4 | 135 | Mid and South Essex NHS Foundation TrustOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT00180739 | Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future | withdrawn | Phase 4 | 0 | Imperial College LondonOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT01995513 | Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients(PLATO) | completed | Phase 4 | 509 | PfizerINDUSTRY | 11 | Sep 18, 2023 | clinicaltrials |
| NCT04854018 | Indo-cyanine Green (ICG) in Paediatric Oncology MIS | completed | Phase 4 | 20 | Birmingham Women's and Children's NHS Foundation TrustOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT02869789 | An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers | completed | Phase 4 | 1,041 | Bristol-Myers SquibbINDUSTRY | 21 | Jun 15, 2023 | clinicaltrials |
| NCT04255134 | Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)(BIORA-PAIN) | completed | Phase 4 | 18 | St George's, University of LondonOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT02476968 | To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer(ORZORA) | completed | Phase 4 | 181 | AstraZenecaINDUSTRY | 8 | Sep 10, 2022 | clinicaltrials |
| NCT03333655 | Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy | completed | Phase 4 | 15 | Hoffmann-La RocheINDUSTRY | 5 | Aug 12, 2022 | clinicaltrials |
| NCT03727750 | Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML | completed | Phase 4 | 51 | PfizerINDUSTRY | 6 | Mar 25, 2022 | clinicaltrials |
| NCT02092467 | Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis | completed | Phase 4 | 4,372 | PfizerINDUSTRY | 30 | Aug 17, 2021 | clinicaltrials |
Data updated 5 days agoSource updated unknownsource: clinicaltrials